Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Onconetix ( (ONCO) ) has shared an announcement.
On December 6, 2025, Proteomedix AG, a subsidiary of Onconetix, Inc., amended its license agreement with Labcorp to conduct a new validation study for Proclarix, a prostate cancer risk identification tool. The amendment stipulates that Labcorp will not pay royalties for using the risk calculator in the study, while Onconetix will compensate Labcorp up to $300,000 based on milestone achievements during the study.
Spark’s Take on ONCO Stock
According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.
Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.
To see Spark’s full report on ONCO stock, click here.
More about Onconetix
Onconetix, Inc. operates in the biotechnology industry, focusing on the development and commercialization of diagnostic products for cancer risk assessment. Its subsidiary, Proteomedix AG, is involved in licensing agreements to leverage intellectual property for product development.
Average Trading Volume: 114,317
Technical Sentiment Signal: Sell
Current Market Cap: $4.35M
For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.